Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Zacks.com on MSN14h
FTC Report Reveals PBM Practices Impacting Competition and Drug CostsThe FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
The nation’s three largest PBMs – CVS Health’s Caremark, Cigna’s Express Scripts and UnitedHealth Group’s Optum Rx – inflated ...
The U.S. Federal Trade Commission on Tuesday published the second part of its investigation into how prescription drug ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and ...
The U.S. Food and Drug Administration today issued a proposed rule to limit nicotine levels in cigarettes and other combusted (smoked) tobacco products to minimally addictive or non-addictive levels, ...
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...
A new report published by THE SAGE GROUP reviews recent calcium research and quantifies the number of CLI patients with calcified leg arteries. "Almost all CLI patients have arterial calcification.
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
Pharmacy benefit managers "are raking in billions in excess revenue—$7.3 billion over just five years—while squeezing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback